Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-clear Cell Renal Cell Carcinoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Non-clear cell renal cell carcinoma (nccRCC) is a highly heterogeneous group of kidney cancer entities
Bergmann et al. 2021 Expert Review of Anticancer Therapy 21(11): 1273-1286

25%–30% of patients diagnosed with Renal Cell Carcinoma have Non-clear Cell Renal Cell Carcinoma (nccRCC), which includes Papillary (types I and II) Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma (ChRCC), mucinous tubular and spindle cell (MTSC), Xp11.2 translocation, medullary, and unclassiﬁed Renal Cell Carcinoma.
Hahn et al. 2020

When compared with metastatic [Clear Cell Renal Cel…

References (Sources)

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Chanzá et al. 2019 Lancet Oncol 20: 581-90
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
Kroeger et al. 2013 Cancer 119: 2999-3006
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
McDermott et al. 2021a
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
Bergmann et al. 2021 Expert Review of Anticancer Therapy 21(11): 1273-1286
Review
Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma
Hahn et al. 2020

AI Chat

7/1/2026

Chat with our artificial intelligence: